Cited 0 times in Scipus Cited Count

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.

DC Field Value Language
dc.contributor.authorSohn, YB-
dc.contributor.authorCho, SY-
dc.contributor.authorLee, J-
dc.contributor.authorKwun, Y-
dc.contributor.authorHuh, R-
dc.contributor.authorJin, DK-
dc.date.accessioned2017-04-25T06:36:50Z-
dc.date.available2017-04-25T06:36:50Z-
dc.date.issued2015-
dc.identifier.issn1096-7192-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13918-
dc.description.abstractIdursulfase beta (Hunterase®) has been used for enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) aged 6 years or older since 2012 in Korea. The objective of this study was to evaluate the safety and efficacy of ERT with idursulfase beta in Hunter syndrome children younger than 6 years. This study was a 52-week, single center, single arm, open-label clinical trial (NCT01645189). Idursulfase beta (0.5mg/kg/week) was administered intravenously for 52 weeks. The primary endpoint was safety assessed by adverse events (AEs). Secondary endpoints included vital signs, physical examination, ECG, laboratory tests, anti-idursulfase antibodies, and efficacy represented by changes in urinary glycosaminoglycan (GAG) at week 53 from baseline. In addition, growth indices and developmental milestones (Denver II test) were evaluated as exploratory variables. All six patients experienced at least one AE. A total of 109 AEs were reported. One patient experienced a serious AE (hospitalization due to gastroenteritis) that was considered not to be treatment related. One patient (16.7%) experienced infusion-related adverse drug reactions (ADRs), developing urticaria six times and a cough five times. There were no serious ADRs and no clinically significant changes in vital signs, physical exam, laboratory parameters, or ECG. Of the six patients, four (66.7%) showed anti-idursulfase antibodies and neutralizing antibodies on at least one occasion during the study. At week 53, urinary GAG was significantly reduced by -35.1±30.6mgGAG/g creatine from baseline (P=0.038). This study indicates that the safety and efficacy of idursulfase beta are similar to those reported in Hunter syndrome patients aged 6 years or older.-
dc.language.isoen-
dc.subject.MESHAdministration, Intravenous-
dc.subject.MESHAntibodies-
dc.subject.MESHAntibodies, Neutralizing-
dc.subject.MESHChild-
dc.subject.MESHChild, Preschool-
dc.subject.MESHEnzyme Replacement Therapy-
dc.subject.MESHGlycosaminoglycans-
dc.subject.MESHHumans-
dc.subject.MESHIduronate Sulfatase-
dc.subject.MESHInfant-
dc.subject.MESHMale-
dc.subject.MESHMucopolysaccharidosis II-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTreatment Outcome-
dc.titleSafety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.-
dc.typeArticle-
dc.identifier.pmid25219292-
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S1096-7192(14)00274-1-
dc.contributor.affiliatedAuthor손, 영배-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.ymgme.2014.08.009-
dc.citation.titleMolecular genetics and metabolism-
dc.citation.volume114-
dc.citation.number2-
dc.citation.date2015-
dc.citation.startPage156-
dc.citation.endPage160-
dc.identifier.bibliographicCitationMolecular genetics and metabolism, 114(2). : 156-160, 2015-
dc.identifier.eissn1096-7206-
dc.relation.journalidJ010967192-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Genetics
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse